# D-0502

Source: https://onco.cc/drugs/d-0502/  
OnCo record `d-0502` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

D-0502 is an experimental small-molecule drug from InventisBio in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.

## Summary

D-0502 is a small-molecule drug developed by InventisBio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial. ClinicalTrials.gov describes the intervention as: * Dosage form: Tablet * Administration route: Oral, once a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT06954961, plans to enrol 640 participants with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial.

## Sources

- ClinicalTrials.gov: trials of D-0502: https://clinicaltrials.gov/search?intr=D-0502
- Sponsor pipeline page: https://www.inventisbio.com/en/pipeline

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/)
- trials: [A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct06954961/)

---
JSON: https://onco.cc/api/v1/entities/d-0502.json